OTC Tylenol Sales Could Shrink By Half With Acetaminophen Dose Restriction
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson could lose roughly $500 million in nonprescription Tylenol sales if FDA follows an advisory committee recommendation to switch 500-g tablets of acetaminophen to Rx status
You may also be interested in...
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.
McNeil Lowers Recommended Maximum Dose For Extra Strength Tylenol
McNeil Consumer Healthcare lowers the maximum daily dose indicated on labels of Extra Strength Tylenol, the first in a series of dosing changes for the firm’s acetaminophen-containing products.